Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of ...

Liraglutide compared with placebo (a sham medication) likely increases the number of people who lose at least 5% of their body weight, but its impact on unwanted effects, quality of life, and major ...

According to a new scientific statement from the American Heart Association, disruptions to our natural circadian rhythm—the ...

A new American Heart Association scientific statement highlights how maintaining circadian health through regular sleep, light exposure, meal timing, and exercise may reduce cardiometabolic disease ...

A new study found that walking for longer stretches at a time, ie. for 10 minutes or more, was associated with a lower risk ...

People with poor sleep and obesity have a much higher risk of multimorbidity—having two or more chronic diseases at the same ...

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...

For the first time in over a decade, obesity rates in the US are down, from 39% to 37.7%. Meanwhile, the use of GLP-1 ...

Over one in 150 births ended in a stillbirth, with a significantly higher rate of one in 112 in low-income areas.

Somehow, it’s becoming even harder to get a GLP-1.

New research reveals that one in five people with normal BMIs have hidden abdominal obesity, facing 29% higher blood pressure ...